ijms-logo

Journal Browser

Journal Browser

Recent Advances in Immuno-Oncology and Intercellular Communication

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Biology".

Deadline for manuscript submissions: closed (31 October 2023) | Viewed by 14871

Special Issue Editors


E-Mail Website
Guest Editor
Institute of Fundamental Medicine and Biology, Kazan (Volga Region) Federal University, 420008 Kazan, Russia
Interests: cell culture; PCR; flow cytometry; western blot analysis; gel electrophoresis; gene expression; electrophoresis; immunofluorescence; SDS-PAGE; DNA extraction
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Laboratory of Molecular Immunology, Institute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia
Interests: immuno-oncology
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Institute of Fundamental Medicine and Biology, Department of Genetics, Kazan Federal University, Kazan, Russia
Interests: multi-omics medicine; precision medicine; regenerative medicine; gene and cell therapy; molecular neurobiology; molecular virology; cancer diagnostics and therapy
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

For this Special Issue of the International Journal of Molecular Sciences, we invite you to contribute either an original research article or a review article on any aspect of the subject of “Recent Advances in Immuno-Oncology and Intercellular Communication”. Understanding the basic mechanisms of  tumorigenesis, role of the immune system, and intercellular communication in cancer is pivotal for the development of novel therapeutics.

Potential topics include but are not limited to:

  • Key biological processes such as cell metabolism and signaling pathways;
  • Molecular mechanisms underlying cancer progression;
  • Crosstalk between tumor and immune cells;
  • Cancer biomarkers: screening, diagnosis, treatment response, prognosis;
  • Cancer cell invasion and metastasis;
  • Intercellular communication in the tumor microenvironment;
  • Communication between adjacent cells through tunneling nanotubes (TNT), extracellular vesicles or soluble factors;
  • Advances in cancer immunotherapy;
  • Translational cancer research;
  • EVs as a therapeutic tool.

Dr. Marina Gomzikova
Prof. Dr. Hans-Uwe Simon
Prof. Dr. Albert Rizvanov
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • intercellular communication
  • immune cells
  • tumor
  • cancers
  • inflammatory

Published Papers (4 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

24 pages, 7638 KiB  
Article
GRP94 Inhabits the Immortalized Porcine Hepatic Stellate Cells Apoptosis under Endoplasmic Reticulum Stress through Modulating the Expression of IGF-1 and Ubiquitin
by Xiaohong Wang, Hairui Xin, Chuang Zhang, Xianhong Gu and Yue Hao
Int. J. Mol. Sci. 2022, 23(22), 14059; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms232214059 - 14 Nov 2022
Cited by 2 | Viewed by 1651
Abstract
Endoplasmic reticulum stress (ERS) is closely related to the occurrence and progression of metabolic liver disease. The treatment targeting glucose-regulated protein 94 (GRP94) for liver disease has gotten much attention, but the specific effect of GRP94 on hepatocyte apoptosis is still unclear. So [...] Read more.
Endoplasmic reticulum stress (ERS) is closely related to the occurrence and progression of metabolic liver disease. The treatment targeting glucose-regulated protein 94 (GRP94) for liver disease has gotten much attention, but the specific effect of GRP94 on hepatocyte apoptosis is still unclear. So far, all the studies on GRP94 have been conducted in mice or rats, and little study has been reported on pigs, which share more similarities with humans. In this study, we used low-dose (LD) and high-dose (HD) tunicamycin (TM) to establish ERS models on piglet livers and immortalized porcine hepatic stellate cells (HSCs). On the piglet ERS model we found that ERS could significantly (p < 0.01) stimulate the secretion and synthesis of insulin-like growth factor (IGF-1), IGF-1 receptor (IGF-1R), and IGF-binding protein (IGFBP)-1 and IGFBP-3; however, with the increase in ERS degree, the effect of promoting secretion and synthesis significantly (p < 0.01) decreased. In addition, the ubiquitin protein and ubiquitination-related gene were significantly increased (p < 0.05) in the LD group compared with the vehicle group. The protein level of Active-caspase 3 was significantly increased (p < 0.01) in the HD group, however, the TUNEL staining showed there was no significant apoptosis in the piglet liver ERS model. To explore the biofunction of ER chaperone GRP94, we used shRNA to knock down the expression of GRP94 in porcine HSCs. Interestingly, on porcine HSCs, the knockdown of GRP94 significantly (p < 0.05) decreased the secretion of IGF-1, IGFBP-1 and IGFBP-3 under ERS, but had no significant effect on these under normal condition, and knockdown GRP94 had a significant (p < 0.01) effect on the UBE2E gene and ubiquitin protein from the analysis of two-way ANOVA. On porcine HSCs apoptosis, the knockdown of GRP94 increased the cell apoptosis in TUNEL staining, and the two-way ANOVA analysis shows that knockdown GRP94 had a significant (p < 0.01) effect on the protein levels of Bcl-2 and Caspase-3. For CCK-8 assay, ERS had a significant inhibitory(p < 0.05) effect on cell proliferation when treated with ERS for 24 h, and both knockdown GRP94 and ERS had a significant inhibitory(p < 0.05) effect on cell proliferation when treated with ERS for 36 h and 48 h. We concluded that GRP94 can protect the cell from ERS-induced apoptosis by promoting the IGF-1 system and ubiquitin. These results provide valuable information on the adaptive mechanisms of the liver under ERS, and could help identify vital functional genes to be applied as possible diagnostic biomarkers and treatments for diseases induced by ERS in the future. Full article
(This article belongs to the Special Issue Recent Advances in Immuno-Oncology and Intercellular Communication)
Show Figures

Figure 1

Review

Jump to: Research

17 pages, 755 KiB  
Review
Tracking of Extracellular Vesicles’ Biodistribution: New Methods and Approaches
by Alexander M. Aimaletdinov and Marina O. Gomzikova
Int. J. Mol. Sci. 2022, 23(19), 11312; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms231911312 - 25 Sep 2022
Cited by 24 | Viewed by 4568
Abstract
Extracellular vesicles (EVs) are nanosized lipid bilayer vesicles that are released by almost all cell types. They range in diameter from 30 nm to several micrometres and have the ability to carry biologically active molecules such as proteins, lipids, RNA, and DNA. EVs [...] Read more.
Extracellular vesicles (EVs) are nanosized lipid bilayer vesicles that are released by almost all cell types. They range in diameter from 30 nm to several micrometres and have the ability to carry biologically active molecules such as proteins, lipids, RNA, and DNA. EVs are natural vectors and play an important role in many physiological and pathological processes. The amount and composition of EVs in human biological fluids serve as biomarkers and are used for diagnosing diseases and monitoring the effectiveness of treatment. EVs are promising for use as therapeutic agents and as natural vectors for drug delivery. However, the successful use of EVs in clinical practice requires an understanding of their biodistribution in an organism. Numerous studies conducted so far on the biodistribution of EVs show that, after intravenous administration, EVs are mostly localized in organs rich in blood vessels and organs associated with the reticuloendothelial system, such as the liver, lungs, spleen, and kidneys. In order to improve resolution, new dyes and labels are being developed and detection methods are being optimized. In this work, we review all available modern methods and approaches used to assess the biodistribution of EVs, as well as discuss their advantages and limitations. Full article
(This article belongs to the Special Issue Recent Advances in Immuno-Oncology and Intercellular Communication)
Show Figures

Figure 1

20 pages, 1132 KiB  
Review
Role of Mesenchymal Stem Cells and Extracellular Vesicles in Idiopathic Pulmonary Fibrosis
by Sevindzh Kletukhina, Guzel Mutallapova, Angelina Titova and Marina Gomzikova
Int. J. Mol. Sci. 2022, 23(19), 11212; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms231911212 - 23 Sep 2022
Cited by 9 | Viewed by 3675
Abstract
Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial fibrotic disease that leads to disability and death within 5 years of diagnosis. Pulmonary fibrosis is a disease with a multifactorial etiology. The concept of aberrant regeneration of the pulmonary epithelium reveals the pathogenesis of [...] Read more.
Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial fibrotic disease that leads to disability and death within 5 years of diagnosis. Pulmonary fibrosis is a disease with a multifactorial etiology. The concept of aberrant regeneration of the pulmonary epithelium reveals the pathogenesis of IPF, according to which repeated damage and death of alveolar epithelial cells is the main mechanism leading to the development of progressive IPF. Cell death provokes the migration, proliferation and activation of fibroblasts, which overproduce extracellular matrix, resulting in fibrotic deformity of the lung tissue. Mesenchymal stem cells (MSCs) and extracellular vesicles (EVs) are promising therapies for pulmonary fibrosis. MSCs, and EVs derived from MSCs, modulate the activity of immune cells, inhibit the expression of profibrotic genes, reduce collagen deposition and promote the repair of damaged lung tissue. This review considers the molecular mechanisms of the development of IPF and the multifaceted role of MSCs in the therapy of IPF. Currently, EVs-MSCs are regarded as a promising cell-free therapy tool, so in this review we discuss the results available to date of the use of EVs-MSCs for lung tissue repair. Full article
(This article belongs to the Special Issue Recent Advances in Immuno-Oncology and Intercellular Communication)
Show Figures

Figure 1

15 pages, 1061 KiB  
Review
Methods of the Large-Scale Production of Extracellular Vesicles
by Valeriia Syromiatnikova, Angelina Prokopeva and Marina Gomzikova
Int. J. Mol. Sci. 2022, 23(18), 10522; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms231810522 - 10 Sep 2022
Cited by 40 | Viewed by 4483
Abstract
To date, extracellular vesicles (EVs) have been extensively investigated as potential substitutes for cell therapy. Research has suggested their ability to overcome serious risks associated with the application of these cells. Although, the translation of EVs into clinical practice is hampered by the [...] Read more.
To date, extracellular vesicles (EVs) have been extensively investigated as potential substitutes for cell therapy. Research has suggested their ability to overcome serious risks associated with the application of these cells. Although, the translation of EVs into clinical practice is hampered by the lack of a cheap reasonable way to obtain a clinically relevant number of EVs, an available method for the large-scale production of EVs ensures vesicles’ integrity, preserves their biological activity, and ensures they are well reproducible, providing homogeneity of the product from batch to batch. In this review, advances in the development of methods to increase EVs production are discussed. The existing approaches can be divided into the following: (1) those based on increasing the production of natural EVs by creating and using high capacity “cell factories”, (2) those based on the induction of EVs secretion under various cell stressors, and (3) those based on cell fragmentation with the creation of biomimetic vesicles. The aim of this review is to stimulate the introduction of EVs into clinical practice and to draw attention to the development of new methods of EVs production on a large scale. Full article
(This article belongs to the Special Issue Recent Advances in Immuno-Oncology and Intercellular Communication)
Show Figures

Figure 1

Back to TopTop